Cesca Therapeutics Inc  

(Public, NASDAQ:KOOL)   Watch this stock  
Find more results for Marrow
1.18
-0.03 (-2.48%)
Sep 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.17 - 1.23
52 week 0.71 - 3.24
Open 1.20
Vol / Avg. 55,287.00/76,228.00
Mkt cap 48.63M
P/E     -
Div/yield     -
EPS -0.44
Shares 40.19M
Beta 1.22
Inst. own 13%
Sep 25, 2014
Q4 2014 Cesca Therapeutics Inc Earnings Call
Sep 25, 2014
Q4 2014 Cesca Therapeutics Inc Earnings Release
Sep 9, 2014
Cesca Therapeutics Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -46.04% -17.18%
Operating margin -46.04% -17.06%
EBITD margin - -25.19%
Return on average assets -24.25% -15.58%
Return on average equity -29.32% -21.13%
Employees 66 -
CDP Score - -

Address

2711 Citrus Road
RANCHO CORDOVA, CA 95742
United States - Map
+1-916-8585100 (Phone)
+1-916-8585199 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cesca Therapeutics Inc, formerly ThermoGenesis Corp., designs, develops and commercializes devices and disposable tools for the processing, storage and administration of cell and tissue therapies used in the practice of regenerative medicine. The Company's products automate the volume reduction and cryopreservation of adult stem cell concentrates from cord blood and bone marrow for use in laboratory and point of care settings. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. The Company provides products and technologies to enables cell separation, processing and cryopreservation for storage of biological fluids, including umbilical cord blood, peripheral blood and bone marrow in a format. In February 2014, the Company consummated the merger with TotipotentRX Corporation.

Officers and directors

Craig W. Moore Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Kenneth L. Harris President, Director
Age: 50
Bio & Compensation  - Reuters
Matthew T. Plavan CPA Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Dan T. Bessey Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Ken Pappa Vice President - Manufacturing and Engineering
Age: 52
Bio & Compensation  - Reuters
Tim Lee Director - International Sales
Bio & Compensation  - Reuters
Mitchel Sivilotti Chief Biologist
Age: 36
Bio & Compensation  - Reuters
Mahendra S. Rao M.D., Ph.D. Director
Age: 52
Bio & Compensation  - Reuters
Patrick J. McEnany Independent Director
Age: 66
Bio & Compensation  - Reuters
Robin C. Stracey Independent Director
Age: 55
Bio & Compensation  - Reuters